Prof Sia Daneshmand
Dr. Sia Daneshmand is a Professor of Urology and Medicine (Oncology) with Clinical Scholar designation at the University of Southern California (USC) in Los Angeles. He serves as the Director of Urologic Oncology and the Fellowship Director for the Society of Urologic Oncology (SUO) Fellowship. His primary clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. Dr. Daneshmand is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer. He is among the highest-volume surgeons for this disease in the country.
His research focuses on optimizing perioperative outcomes following radical cystectomy and post-chemotherapy RPLND, utilizing serum and molecular markers, and integrating new technologies in the diagnosis and management of bladder and testicular cancers. He also investigates functional outcomes following orthotopic urinary diversion. Dr. Daneshmand serves on the American Urological Association (AUA) Guidelines Panels for both non-muscle invasive bladder cancer and testicular cancer. He is the Chair of the Bladder Cancer Section of the SUO Clinical Trials Consortium (SUO-CTC) and a member of the scientific steering committees for several bladder cancer clinical trials. He has led over a dozen clinical trials in bladder cancer, as well as a pivotal investigator- initiated, multi-institutional trial in testicular cancer (SEMS).
He is the President-Elect of the Western Section of the AUA and a member of the Alpha Omega Alpha medical honor society. For 15 consecutive years, he has been recognized as one of “America’s Top Cancer Doctors.” A career leader in academic research on bladder cancer and germ cell tumors, he also serves as Chair of the SWOG Local Bladder cancer Committee. Dr. Daneshmand has been a visiting professor at more than 25 institutions worldwide and has presented over 500 abstracts at scientific meetings. He has authored or co authored more than 400 peer-reviewed articles, reviews, and book chapters.